PACE-CME

The journey from hypothesis to reality on inflammation in CVD

The journey from hypothesis to reality on inflammation in CVD
RestartResume
10' education - Apr. 28, 2022 - Prof. Peter Libby, MD and prof. Paul Ridker, MD

Subtitles: Italian, English, German & more

  • Overview

    On the topic of inflammation in CVD, prof. Libby and Ridker discuss the journey from theory to testing the hypothesis to reality. "Ultimately, the inflammation hypothesis is going to yield great dividends for our patients", concluded prof. Libby.

  • Educational information

    This discussion by Peter Libby and Paul Ridker is part of a series titled "Inflammation: The next therapeutic frontier in targeting cardiovascular risk". This series consists of an introduction, three lectures and a discussion in which four experts in this field will bring you up to date on the role of inflammation in atherosclerosis and how to translate findings from science and clinical trials into practice.

  • Faculty

    Peter Libby is a cardiovascular medicine specialist at Brigham and Women’s Hospital and the Mallinckrodt Professor of Medicine at Harvard Medical School, Boston, MA, USA.

    Paul M Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women’s Hospital in Boston, MA, USA.

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant received from Novo Nordisk.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free